Oruka Therapeutics Inc. Common Stock vs Direxion Daily 20 Year Treasury Bull 3X Shares — how do they compare? Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.18B), while Direxion Daily 20 Year Treasury Bull 3X Shares trades at $27.65 (market cap $2.08B). The key difference: Oruka Therapeutics Inc. Common Stock is far larger — about 2.5× Direxion Daily 20 Year Treasury Bull 3X Shares's market cap, and Oruka Therapeutics Inc. Common Stock is trading nearer its 52-week high, Direxion Daily 20 Year Treasury Bull 3X Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Oruka Therapeutics Inc. Common Stock for 0 Days and Direxion Daily 20 Year Treasury Bull 3X Shares for 30 Days on average.
| ORKA | TMF | |
|---|---|---|
Market Cap | $5.18B | $2.08B |
Volume | 490,798 | 5,652,065 |
Sector | Health | Fixed Income |
52-Week High | $113.08 | $44.14 |
52-Week Low | $26.19 | $25.19 |
Typical Hold Time | 0 Days | 30 Days |
Enterprise Value | $4.31B | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TMF, a leveraged ETF tracking long-term Treasury bonds, trades at $26.38, up 1.15% with elevated volume. Technical indicators are bearish overall, with moving averages and oscillators signaling caution. The stock lacks traditional fundamental metrics like P/E or revenue, as it is an ETF, and its value is tied to interest rate expectations. Recent news highlights strong trading volume, suggesting heightened investor attention amid bond market volatility.
The outlook for TMF hinges on interest rate trends, with potential upside if rates fall but significant downside risk if they rise. Investors face volatility from macroeconomic shifts and the ETF's leveraged structure, which amplifies gains and losses. Key risks include Federal Reserve policy changes and inflation dynamics, making it suitable only for those comfortable with high risk and short-term trading.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →TMF is a leveraged ETF that seeks to provide 300% (3x) of the daily performance of the ICE U.S. Treasury 20+ Year Bond Index. It is a tactical instrument used by sophisticated traders to capitalize on declining interest rates or to hedge against equity market volatility. Due to its daily reset mechanism and high expense ratio, TMF is structurally designed for short-term speculation rather than long-term buy-and-hold investing.
Read more on TMF →